• Antiangiogenic agents. Corn said blocking angiogenesis to inhibit tumor growth has successfully treated a variety of different metastatic tumor types, including kidney, colon, and lung cancers. Drugs in clinical trials for treating mCRPC include bevacizumab and thalidomide. Corn said fewer studies have been done with thalidomide because of its potential toxic effects and unknown mechanism for angiogenesis inhibition. In a phase II trial expected to fi nish in mid-2012, mCRPC patients receive a combination of lenalidomide, bevacizumab, and prednisone.
• Androgen-ablative agents. MDV3100 is a new small-molecule androgen receptor (AR) antagonist that overcomes resistance to conventional antiandrogens. Like other antiandrogens, such as bicalutamide, MDV3100 inhibits AR function by blocking AR ligand binding, nuclear translocation, and DNA binding. In the past 15 months, the U.S. Food and Drug Administration approved two agents that prolong life in mCRPC patients -abiraterone (Zytiga), a drug that blocks all physiologic sources of testosterone, and cabazitaxel (Jevtana), a new taxane.
• Targeted agents. Dasatinib is an oral tyrosine kinase inhibitor. In a phase II trial, data suggested only modest clinical activity for dasatinib alone. However, Corn said dasatinib ' s ability to modulate both the epithelial and stromal compartments prompted a phase III study combining dasatinib with docetaxel in mCRPC patients. Dovitinib and XL-184 ( cabozantinib) are also in phase II trials.
• Immunotherapy. FDA has also approved the immunostimulant sipuleucel-T (Provenge).
Drugs for treating mCRPC might treat other prostate cancers, but determining that would require "a much more detailed analysis," according to Corn. He is optimistic that basic science is leading to a greater appreciation for what makes prostate cancers tick. "It ' s very exciting to see these abstract notions leading to the development of real practical drugs that are helping people in meaningful ways," he said.
